Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + bevacizumab with SBRT for portal vein tumor thrombus in first-line hepatocellular carcinoma
ChiCTR2100047433Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Primary endpoints: Safety and Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100047433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047433.